IP Library › Granted Patent US 12,479,913
Granted Patent B2
US 12,479,913 · App. 18/333,882 · Granted Nov 25, 2025

Polynucleotide encoding anti-TIGIT and anti-CD96 antibodies

Inventors: Dhan Sidhartha Chand (Lexington, MA); Zahra Jawad (Lexington, MA); Olga Ignatovich (Cambridge, GB); Nicola Anne Ramsay (Lexington, MA); Spencer Campbell (Essex, GB); Beth Wensley (Lexington, MA); Emmanuel Cyrille Pascal Briend (Cambridge, GB); K. Mark Bushell (Lexington, MA); Benjamin Maxime Morin (Somerville, MA); Veronica Franciszka Ilkow (Lexington, MA)
Assignee: AGENUS INC.
C07K16/2803A61P35/00A61K2039/505C07K2317/31C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,479,913
App. No.
18/333,882
Granted
Nov 25, 2025
Kind
B2
Abstract

The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.

Claims (106)

1 . A polynucleotide encoding the first heavy chain variable region (VH), the first light chain variable region (VL), the second VH, and the second VL, of a multispecific molecule comprising:

(a) a first antigen-binding region that specifically binds to human CD96, the first antigen-binding region comprising a first VH comprising CDRs CDRH1, CDRH2, and CDRH3, and a first VL comprising CDRs CDRL1, CDRL2, and CDRL3, wherein the first VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence of SEQ ID NO: 38, and the first VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence of SEQ ID NO: 39; and

(b) a second antigen-binding region that specifically binds to human TIGIT, the second antigen-binding region comprising a second VH comprising CDRs CDRH1, CDRH2, and CDRH3, and a second VL comprising CDRs CDRL1, CDRL2, and CDRL3, wherein the second VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence of SEQ ID NO: 40; and the second VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence of SEQ ID NO: 41.

2 . The polynucleotide of claim 1 , wherein:

(a) the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the first antigen-binding region comprise the amino acid sequences of SEQ ID NOs: 22, 23, 24, 25, 26, and 27, respectively; and/or

(b) the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the second antigen-binding region comprise the amino acid sequences of SEQ ID NOs: 28, 29, 30, 31, 32, and 33, respectively.

3 . The polynucleotide of claim 1 , wherein:

(a) the first VH comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of the amino acid sequence of SEQ ID NO: 38;

(b) the first VL comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of the amino acid sequence of SEQ ID NO: 39;

(c) the second VH comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of the amino acid sequence of SEQ ID NO: 40; and/or

(d) the second VL comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of the amino acid sequence of SEQ ID NO: 41.

4 . The polynucleotide of claim 1 , wherein:

(a) the first VH comprises the amino acid sequence of SEQ ID NO: 38;

(b) the first VL comprises the amino acid sequence of SEQ ID NO: 39;

(c) the second VH comprises the amino acid sequence of SEQ ID NO: 40; and

(d) the second VL comprises the amino acid sequence of SEQ ID NO: 41.

5 . The polynucleotide of claim 1 , wherein, the first antigen-binding region and/or the second antigen-binding region comprises a human heavy chain constant region selected from the group consisting of IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 , and IgA 2 .

6 . The polynucleotide of claim 5 , wherein:

(a) the first antigen-binding region comprises a first human IgG heavy chain constant region comprising aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, and the second antigen-binding region comprises a second human IgG heavy chain constant region comprising aspartate, leucine, glutamate, and tryptophan at amino acid positions 239, 330, 332, and 366, respectively; or

(b) the first antigen-binding region comprises a first human IgG heavy chain constant region comprising aspartate, leucine, glutamate, and tryptophan at amino acid positions 239, 330, 332, and 366, respectively, and the second antigen-binding region comprises a second human IgG heavy chain constant region comprising aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively,

wherein the amino acid positions are numbered according to the EU numbering system.

7 . The polynucleotide of claim 5 , wherein:

(a) the first antigen-binding region comprises a first heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 50, and the second antigen-binding region comprises a second heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 56; or

(b) the first antigen-binding region comprises a first heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 56, and the second antigen-binding region comprises a second heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 50.

8 . The polynucleotide of claim 5 , wherein:

(a) the first antigen-binding region comprises a first heavy chain comprising the amino acid sequence of SEQ ID NO: 5, and a first light chain comprising the amino acid sequence of SEQ ID NO: 6; and

(b) the second antigen-binding region comprises a second heavy chain comprising the amino acid sequence of SEQ ID NO: 7, and a second light chain comprising the amino acid sequence of SEQ ID NO: 9.

9 . A vector or plurality of vectors comprising the polynucleotide of claim 2 .

10 . A recombinant host cell comprising:

(a) a polynucleotide encoding the first VH and first VL of claim 2 ;

(b) a polynucleotide encoding the second VH and second VL of claim 2 ;

(c) a first polynucleotide encoding the first VH of claim 2 and a second polynucleotide encoding the first VL of claim 2 ;

(d) a first polynucleotide encoding the second VH of claim 2 and a second polynucleotide encoding the second VL of claim 2 ;

(e) a first polynucleotide encoding the first VH and first VL of claim 2 , and a second polynucleotide encoding the second VH and second VL of claim 2 ;

(f) a first polynucleotide encoding the first VH of claim 2 , a second polynucleotide encoding the first VL of claim 2 , a third polynucleotide encoding the second VH of claim 2 , and a fourth polynucleotide encoding the second VL of claim 2 ;

(g) a polynucleotide encoding a heavy chain comprising the first VH and a light chain comprising the first VL of claim 2 ;

(h) a polynucleotide encoding a heavy chain comprising the second VH and a light chain comprising the second VL of claim 2 ;

(i) a first polynucleotide encoding a heavy chain comprising the first VH and a second polynucleotide encoding a light chain comprising the first VL of claim 2 ;

(j) a first polynucleotide encoding a heavy chain comprising the second VH and a second polynucleotide encoding a light chain comprising the second VL of claim 2 ;

(k) a first polynucleotide encoding a first heavy chain comprising the first VH and a first light chain comprising the first VL of claim 2 , and a second polynucleotide encoding a second heavy chain comprising the second VH and a second light chain comprising the second VL of claim 2 ; or

(l) a first polynucleotide encoding a first heavy chain comprising the first VH of claim 2 , a second polynucleotide encoding a first light chain comprising the first VL of claim 2 , a third polynucleotide encoding a second heavy chain comprising the second VH of claim 2 , and a fourth polynucleotide encoding a second light chain comprising the second VL of claim 2 .

11 . A method of producing an antibody or multispecific molecule, the method comprising culturing the host cell of claim 10 under suitable conditions so that the polynucleotide(s) is (are) expressed and the antibody or multispecific molecule is produced.

12 . A method of producing a multispecific molecule, the method comprising:

(a) (i) expressing in a first cell a first polynucleotide encoding a first heavy chain comprising the first VH of claim 2 and a second polynucleotide encoding a first light chain comprising the first VL of claim 2 , under conditions whereby the first antigen-binding region is produced;

(ii) expressing in a second cell a third polynucleotide encoding a second heavy chain comprising the second VH of claim 2 and a fourth polynucleotide encoding a second light chain comprising the second VL of claim 2 , under conditions whereby the second antigen-binding region is produced; and

(iii) contacting the first and the second antigen-binding regions produced in steps (i) and (ii), under suitable conditions so that the multispecific molecule is produced; or

(b) (i) expressing in a first cell a first polynucleotide encoding a first heavy chain comprising the first VH and a first light chain comprising the first VL of claim 2 , under conditions whereby the first antigen-binding region is produced;

(ii) expressing in a second cell a second polynucleotide encoding a second heavy chain comprising the second VH and a second light chain comprising the second VL of claim 2 , under conditions whereby the second antigen-binding region is produced; and

(iii) contacting the first and the second antigen-binding regions produced in steps (i) and (ii), under suitable conditions so that the multispecific molecule is produced.

13 . A method of producing a multispecific molecule, the method comprising expressing in a cell:

(a) a first polynucleotide encoding a first heavy chain comprising the first VH of claim 2 , a second polynucleotide encoding a first light chain comprising the first VL of claim 2 , a third polynucleotide encoding a second heavy chain comprising the second VH of claim 2 , and a fourth polynucleotide encoding a second light chain comprising the second VL of claim 2 ; or

(b) a first polynucleotide encoding a first heavy chain comprising the first VH and a first light chain comprising the first VL of claim 2 , and a second polynucleotide encoding a second heavy chain comprising the second VH and a second light chain comprising the second VL of claim 2 ,

under suitable conditions so that the polynucleotides are expressed and the multispecific molecule is produced.

14 . A vector or plurality of vectors comprising the polynucleotide of claim 4 .

15 . A recombinant host cell comprising:

(a) a polynucleotide encoding the first VH and first VL of claim 4 ;

(b) a polynucleotide encoding the second VH and second VL of claim 4 ;

(c) a first polynucleotide encoding the first VH of claim 4 and a second polynucleotide encoding the first VL of claim 4 ;

(d) a first polynucleotide encoding the second VH of claim 4 and a second polynucleotide encoding the second VL of claim 4 ;

(e) a first polynucleotide encoding the first VH and first VL of claim 4 , and a second polynucleotide encoding the second VH and second VL of claim 4 ;

(f) a first polynucleotide encoding the first VH of claim 4 , a second polynucleotide encoding the first VL of claim 4 , a third polynucleotide encoding the second VH of claim 4 , and a fourth polynucleotide encoding the second VL of claim 4 ;

(g) a polynucleotide encoding a heavy chain comprising the first VH and a light chain comprising the first VL of claim 4 ;

(h) a polynucleotide encoding a heavy chain comprising the second VH and a light chain comprising the second VL of claim 4 ;

(i) a first polynucleotide encoding a heavy chain comprising the first VH and a second polynucleotide encoding a light chain comprising the first VL of claim 4 ;

(j) a first polynucleotide encoding a heavy chain comprising the second VH and a second polynucleotide encoding a light chain comprising the second VL of claim 4 ;

(k) a first polynucleotide encoding a first heavy chain comprising the first VH and a first light chain comprising the first VL of claim 4 , and a second polynucleotide encoding a second heavy chain comprising the second VH and a second light chain comprising the second VL of claim 4 ; or

(l) a first polynucleotide encoding a first heavy chain comprising the first VH of claim 4 , a second polynucleotide encoding a first light chain comprising the first VL of claim 4 , a third polynucleotide encoding a second heavy chain comprising the second VH of claim 4 , and a fourth polynucleotide encoding a second light chain comprising the second VL of claim 4 .

16 . A method of producing an antibody or multispecific molecule, the method comprising culturing the host cell of claim 15 under suitable conditions so that the polynucleotide(s) are expressed and the antibody or multispecific molecule is produced.

17 . A method of producing a multispecific molecule, the method comprising:

(a) (i) expressing in a first cell a first polynucleotide encoding a first heavy chain comprising the first VH of claim 4 and a second polynucleotide encoding a first light chain comprising the first VL of claim 4 , under conditions whereby the first antigen-binding region is produced;

(ii) expressing in a second cell a third polynucleotide encoding a second heavy chain comprising the second VH of claim 4 and a fourth polynucleotide encoding a second light chain comprising the second VL of claim 4 , under conditions whereby the second antigen-binding region is produced; and

(iii) contacting the first and the second antigen-binding regions produced in steps (i) and (ii), under suitable conditions so that the multispecific molecule is produced; or

(b) (i) expressing in a first cell a first polynucleotide encoding a first heavy chain comprising the first VH and a first light chain comprising the first VL of claim 4 , under conditions whereby the first antigen-binding region is produced;

(ii) expressing in a second cell a second polynucleotide encoding a second heavy chain comprising the second VH and a second light chain comprising the second VL of claim 4 , under conditions whereby the second antigen-binding region is produced; and

(iii) contacting the first and the second antigen-binding regions produced in steps (i) and (ii), under suitable conditions so that the multispecific molecule is produced.

18 . A method of producing a multispecific molecule, the method comprising expressing in a cell:

(a) a first polynucleotide encoding a first heavy chain comprising the first VH of claim 4 , a second polynucleotide encoding a first light chain comprising the first VL of claim 4 , a third polynucleotide encoding a second heavy chain comprising the second VH of claim 4 , and a fourth polynucleotide encoding a second light chain comprising the second VL of claim 4 ; or

(b) a first polynucleotide encoding a first heavy chain comprising the first VH and a first light chain comprising the first VL of claim 4 , and a second polynucleotide encoding a second heavy chain comprising the second VH and a second light chain comprising the second VL of claim 4 ,

under suitable conditions so that the polynucleotides are expressed and the multispecific molecule is produced.

19 . A vector or plurality of vectors comprising the polynucleotide of claim 8 .

20 . A recombinant host cell comprising:

(a) a polynucleotide encoding the first VH and first VL of claim 8 ;

(b) a polynucleotide encoding the second VH and second VL of claim 8 ;

(c) a first polynucleotide encoding the first VH of claim 8 and a second polynucleotide encoding the first VL of claim 8 ;

(d) a first polynucleotide encoding the second VH of claim 8 and a second polynucleotide encoding the second VL of claim 8 ;

(e) a first polynucleotide encoding the first VH and first VL of claim 8 , and a second polynucleotide encoding the second VH and second VL of claim 8 ;

(f) a first polynucleotide encoding the first VH of claim 8 , a second polynucleotide encoding the first VL of claim 8 , a third polynucleotide encoding the second VH of claim 8 , and a fourth polynucleotide encoding the second VL of claim 8 ;

(g) a polynucleotide encoding a heavy chain comprising the first VH and a light chain comprising the first VL of claim 8 ;

(h) a polynucleotide encoding a heavy chain comprising the second VH and a light chain comprising the second VL of claim 8 ;

(i) a first polynucleotide encoding a heavy chain comprising the first VH and a second polynucleotide encoding a light chain comprising the first VL of claim 8 ;

(j) a first polynucleotide encoding a heavy chain comprising the second VH and a second polynucleotide encoding a light chain comprising the second VL of claim 8 ;

(k) a first polynucleotide encoding a first heavy chain comprising the first VH and a first light chain comprising the first VL of claim 8 , and a second polynucleotide encoding a second heavy chain comprising the second VH and a second light chain comprising the second VL of claim 8 ; or

(l) a first polynucleotide encoding a first heavy chain comprising the first VH of claim 8 , a second polynucleotide encoding a first light chain comprising the first VL of claim 8 , a third polynucleotide encoding a second heavy chain comprising the second VH of claim 8 , and a fourth polynucleotide encoding a second light chain comprising the second VL of claim 8 .

21 . A method of producing an antibody or multispecific molecule, the method comprising culturing the host cell of claim 20 under suitable conditions so that the polynucleotide(s) are expressed and the antibody or multispecific molecule is produced.

22 . A method of producing a multispecific molecule, the method comprising:

(a)

(i) expressing in a first cell a first polynucleotide encoding a first heavy chain comprising the first VH of claim 8 and a second polynucleotide encoding a first light chain comprising the first VL of claim 8 , under conditions whereby the first antigen-binding region is produced;

(ii) expressing in a second cell a third polynucleotide encoding a second heavy chain comprising the second VH of claim 8 and a fourth polynucleotide encoding a second light chain comprising the second VL of claim 8 , under conditions whereby the second antigen-binding region is produced; and

(iii) contacting the first and the second antigen-binding regions produced in steps (i) and (ii), under suitable conditions so that the multispecific molecule is produced; or

(b) (i) expressing in a first cell a first polynucleotide encoding a first heavy chain comprising the first VH and a first light chain comprising the first VL of claim 8 , under conditions whereby the first antigen-binding region is produced;

(ii) expressing in a second cell a second polynucleotide encoding a second heavy chain comprising the second VH and a second light chain comprising the second VL of claim 8 , under conditions whereby the second antigen-binding region is produced; and

(iii) contacting the first and the second antigen-binding regions produced in steps (i) and (ii), under suitable conditions so that the multispecific molecule is produced.

23 . A method of producing a multispecific molecule, the method comprising expressing in a cell:

(a) a first polynucleotide encoding a first heavy chain comprising the first VH of claim 8 , a second polynucleotide encoding a first light chain comprising the first VL of claim 8 , a third polynucleotide encoding a second heavy chain comprising the second VH of claim 8 , and a fourth polynucleotide encoding a second light chain comprising the second VL of claim 8 ; or

(b) a first polynucleotide encoding a first heavy chain comprising the first VH and a first light chain comprising the first VL of claim 8 , and a second polynucleotide encoding a second heavy chain comprising the second VH and a second light chain comprising the second VL of claim 8 ,

under suitable conditions so that the polynucleotides are expressed and the multispecific molecule is produced.

Assignments (2)
SECURITY INTEREST Recorded Mar 31, 2025
From: AGENUS, INC.
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 070680/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2023
From: CHAND, DHAN SIDHARTHA; JAWAD, ZAHRA; IGNATOVICH, OLGA; RAMSAY, NICOLA ANNE; CAMPBELL, SPENCER; WENSLEY, BETH; BRIEND, EMMANUEL CYRILLE PASCAL; BUSHELL, K. MARK; MORIN, BENJAMIN MAXIME; ILKOW, VERONICA FRANCISZKA
To: AGENUS INC.
Reel/Frame 065977/0668 →
Continuity (4)
Division 17818840 · Aug 10, 2022
Continuation 17662036 · May 4, 2022
Provisional Application 63201537 · May 4, 2021
Related Publication 20240141039A1 · May 2, 2024
References Cited (145)
US 5225539A · Winter · 1993 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 8211431B2 · Throsby et al. · 2012 [cited by applicant]
US 9499596B2 · Clark et al. · 2016 [cited by applicant]
US 9695238B2 · Gao et al. · 2017 [cited by applicant]
US 9713641B2 · Hicklin et al. · 2017 [cited by applicant]
US 9725515B2 · Anderson et al. · 2017 [cited by applicant]
US RE46534E · Baldwin et al. · 2017 [cited by applicant]
US 9873740B2 · Grogan et al. · 2018 [cited by applicant]
US 10017572B2 · Grogan et al. · 2018 [cited by applicant]
US 10112997B2 · Gurney et al. · 2018 [cited by applicant]
US 10124061B2 · White et al. · 2018 [cited by applicant]
US 10144778B2 · Eisenbach-Schwartz et al. · 2018 [cited by applicant]
US 10189902B2 · Maurer et al. · 2019 [cited by applicant]
US 10329349B2 · Cooper et al. · 2019 [cited by applicant]
US 10501737B2 · Ishii · 2019 [cited by applicant]
US 10537633B2 · Tso et al. · 2020 [cited by applicant]
US 10537637B2 · Sheng et al. · 2020 [cited by applicant]
US 11021537B2 · Chand · 2021 [cited by examiner]
US 11680098B2 · Chand · 2023 [cited by examiner]
US 20050042664A1 · Wu et al. · 2005 [cited by applicant]
US 20090258013A1 · Clark et al. · 2009 [cited by applicant]
US 20130287777A1 · Duffy et al. · 2013 [cited by applicant]
US 20130287797A1 · Heider et al. · 2013 [cited by applicant]
US 20160108123A1 · Freeman et al. · 2016 [cited by applicant]
US 20160152720A1 · Kim et al. · 2016 [cited by applicant]
US 20160193239A1 · Baylin et al. · 2016 [cited by applicant]
US 20160376371A1 · Ravetch et al. · 2016 [cited by applicant]
US 20170037127A1 · Grogan et al. · 2017 [cited by applicant]
US 20170107300A1 · Kuchroo et al. · 2017 [cited by applicant]
US 20170143825A1 · Grogan · 2017 [cited by applicant]
US 20170239338A1 · Szalay et al. · 2017 [cited by applicant]
US 20170260271A1 · Igawa et al. · 2017 [cited by applicant]
US 20170360932A1 · Parry · 2017 [cited by applicant]
US 20180066055A1 · Williams et al. · 2018 [cited by applicant]
US 20180078625A1 · Moon et al. · 2018 [cited by applicant]
US 20180155422A1 · Bhatt et al. · 2018 [cited by applicant]
US 20180169239A1 · Grogan · 2018 [cited by applicant]
US 20180185480A1 · Mandelboim et al. · 2018 [cited by applicant]
US 20180251548A1 · Sabzevari et al. · 2018 [cited by applicant]
US 20180355040A1 · Chand et al. · 2018 [cited by applicant]
US 20180371083A1 · Williams et al. · 2018 [cited by applicant]
US 20190077869A1 · Fiedler et al. · 2019 [cited by applicant]
US 20200040082A1 · Piasecki et al. · 2020 [cited by applicant]
US 20200062859A1 · Piasecki et al. · 2020 [cited by applicant]
US 20200255516A1 · Fu et al. · 2020 [cited by applicant]
US 20200331999A1 · Zhang et al. · 2020 [cited by applicant]
US 20210101977A1 · Chand et al. · 2021 [cited by applicant]
US 20220089732A1 · Chand et al. · 2022 [cited by applicant]
US 20220389095A1 · Ignatovich et al. · 2022 [cited by applicant]
US 20230014036A1 · Chand et al. · 2023 [cited by applicant]
US 20240141047A1 · Chand et al. · 2024 [cited by applicant]
EP 3712170A1 · 2020 [cited by applicant]
WO WO2011109789A2 · 2011 [cited by applicant]
WO 2013165894A2 · 2013 [cited by applicant]
WO WO2013184912A2 · 2013 [cited by applicant]
WO WO2015024060A1 · 2015 [cited by applicant]
WO WO2016004875A1 · 2016 [cited by applicant]
WO WO2016011264A1 · 2016 [cited by applicant]
WO WO2016180781A1 · 2016 [cited by applicant]
WO WO2016191643A2 · 2016 [cited by applicant]
WO WO2017023749A1 · 2017 [cited by applicant]
WO WO2017030823A2 · 2017 [cited by applicant]
WO 2017053748A2 · 2017 [cited by applicant]
WO WO2017040790A1 · 2017 [cited by applicant]
WO WO2017048824A1 · 2017 [cited by applicant]
WO WO2017059095A1 · 2017 [cited by applicant]
WO WO2017062619A2 · 2017 [cited by applicant]
WO WO2017062820A1 · 2017 [cited by applicant]
WO WO2017123981A1 · 2017 [cited by applicant]
WO WO2017223085A2 · 2017 [cited by applicant]
WO WO2018053242A1 · 2018 [cited by applicant]
WO WO2018102536A1 · 2018 [cited by applicant]
WO WO2018183889A1 · 2018 [cited by applicant]
WO WO2018204363A1 · 2018 [cited by applicant]
WO WO2018204405A1 · 2018 [cited by applicant]
WO WO2018229163A1 · 2018 [cited by applicant]
WO WO2018234793A2 · 2018 [cited by applicant]
WO 2019030377A1 · 2019 [cited by applicant]
WO WO2019062832A1 · 2019 [cited by applicant]
WO WO2019091449A1 · 2019 [cited by applicant]
WO WO2019129221A1 · 2019 [cited by applicant]
WO WO2019129261A1 · 2019 [cited by applicant]
WO WO2019137548A1 · 2019 [cited by applicant]
WO WO2019152574A1 · 2019 [cited by applicant]
WO WO2019154415A1 · 2019 [cited by applicant]
WO WO2019165434A1 · 2019 [cited by applicant]
WO WO2019168382A1 · 2019 [cited by applicant]
WO WO2020092554A1 · 2020 [cited by applicant]
WO 2020132034A1 · 2020 [cited by applicant]
WO WO2020185739A1 · 2020 [cited by applicant]
WO 2020242919A1 · 2020 [cited by applicant]
WO WO2020263879A1 · 2020 [cited by applicant]
WO WO2021042019A1 · 2021 [cited by applicant]
Lazar et al., Engineered antibody Fc variants with enhanced effector function, Proc. Natl. Acad. Sci. USA., 103(11):4005-4010, Mar. 6, 2016. [cited by examiner]
Ha et al., Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins, Front. Immunol. 7:394, 16 pages, Oct. 6, 2016. [cited by examiner]
Spasevska et al., Advances in Bispecific Antibodies Engineering: Novel Concepts for Immunotherapies. J. Blood Disorders Transf. 6(1):243, 8 pages, doi:10.4172/2155-9864.1000243, 2015. [cited by examiner]
Agenus, “Corporate Presentation,” Cantor Fitzgerald Global Healthcare Conference. Sep. 2017. [cited by applicant]
Agenus, “Integrated Immunotherapy: Enabling Best-in-Class I—O Combinations,” Non-Confidential Overview. Nov. 2017. [cited by applicant]
Blake et al., “Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy,” Clin Cancer Res. Nov. 1, 2016;22(21):5183-5188. [cited by applicant]
Cattaruzza et al., “Pharmacodynamic biomarkers for anti-TIGIT treatment and prevalence of TIGIT expression in multiple solid tumor types,” OncoMed Pharmaceuticals. 2017. [cited by applicant]
Chauvin et al., “TIGIT and PD-1 impair tumor antigen-specific CD8? T cells in melanoma patients,” J Clin Invest. May 2015;125(5):2046-58. [cited by applicant]
Chew et al., “TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection,” PLoS Pathog. Jan. 7, 2016;12(1):e1005349. [cited by applicant]
Dougall et al., “TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy,” Immunol Rev. Mar. 2017;276(1):112-120. [cited by applicant]
Gur et al., “Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack,” Immunity. Feb. 17, 2015;42(2):344-355. [cited by applicant]
He et al., “CD155T/TIGIT Signaling Regulates CD8 + T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer,” Cancer Res. Nov. 15, 2017;77(22):6375-6388. [cited by applicant]
Hung et al., “TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM,” Oncoimmunology. May 24, 2018;7(8):e1466769. [cited by applicant]
Johnston et al., “The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function,” Cancer Cell. Dec. 8, 2014;26(6):923-937. [cited by applicant]
Joller et al., “Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses,” Immunity. Apr. 17, 2014;40(4):569-81. [cited by applicant]
Kurtulus et al., “TIGIT predominantly regulates the immune response via regulatory T cells,” J Clin Invest. Nov. 2, 2015;125(11):4053-62. [cited by applicant]
Lozano et al., “The TIGIT/CD226 axis regulates human T cell function,” J Immunol. Apr. 15, 2012;188(8):3869-75. [cited by applicant]
Manieri et al., “TIGIT: A Key Inhibitor of the Cancer Immunity Cycle,” Trends Immunol. Jan. 2017;38(1):20-28. [cited by applicant]
Pauken and Wherry, “TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit,” Cancer Cell. Dec. 8, 2014;26(6):785-787. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2018/030453, dated Jul. 17, 2018. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2020/048700, dated Nov. 26, 2020. [cited by applicant]
PCT International Search Report from PCT/US2022/072099 dated Oct. 6, 2022. [cited by applicant]
Roman Aguilera et al, “CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity,” Oncoimmunology. Feb. 1, 2018;7(5):e1424677. [cited by applicant]
Samanta et al., “Structural, mutational and biophysical studies reveal a canonical mode of molecular recognition between immune receptor TIGIT and nectin-2,” Mol Immunol. Jan. 2017;81:151-159. [cited by applicant]
Stanietsky et al., “The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity,” Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63. [cited by applicant]
Stein, “Next generation immunomodulatory antibodies: optimizing therapeutic impact,” 2017. [cited by applicant]
Stengel et al., “Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering,” Proc Natl Acad Sci U S A. Apr. 3, 2012;1… [cited by applicant]
U.S. Appl. No. 17/662,042, filed May 4, 2022. [cited by applicant]
Yu et al., “The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells,” Nat Immunol. Jan. 2009;10(1):48-57. [cited by applicant]
Zhou et al., “Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8 + T Cells,” Front Immunol. Nov. 29, 2018;9:2821. [cited by applicant]
Almagro et. al., “Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy,” Front Immunol. 2018; 8(1751). [cited by applicant]
Chiu ML et al., “Antibody Structure and Function: The Basis for Engineering Therapeutics,” Antibodies (Basel). 2019; 8(55): 1-80. [cited by applicant]
https://www.thermofisher.com/antibody/primary/target/cd96 (accessed from the internet Dec. 23, 2024), 2025. [cited by applicant]
https://atlasantibodies.com/products/primary-antibodies/triple-a-polyclonals/anti-cd96-antibody-hpa066764-100ul/?language=en (accessed from the internet Dec. 23, 2024). [cited by applicant]
https://www.antibodies-online.com/search.php#tezx (accessed from the internet Dec. 23, 2024). [cited by applicant]
https://www.fishersci.com/shop/products/human-cd96-antibody-r-d-systems/AF6199 (accessed from the internet Dec. 23, 24), 2025. [cited by applicant]
Zeng, J.M. et al.: “Human CD 96 gene cloning, expression and identification”., Nan Fand Yi Ke Da Xue Xue Bao. 2011 31(7):1232-5, abstract only. [cited by applicant]
Gorvel et al., “Targeting the “PVR-TIGIT axis” with immune checkpoint therapies”, F1000Research, 2020, 9(F1000 Faculty Rev):354, pp. 1-10. [cited by applicant]
Meibohm, “Pharmacokinetics of Monoclonal Antibodies”, Chapter 3—Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies of Drug Development, 2006, pp. 45-91. [cited by applicant]
Oganesyan et al., “Structural characterization of a mutated, ADCC-enhanced human Fc fragment”, Molecular Immunology, 2008, 45(7): 1872-1882. [cited by applicant]
Ward et al., “Abstract 253: Anti-TIGIT Antibodies Require Enhanced FcGammaR Co-Engagement for Optimal T and NK Cell-Dependent Anti-Tumor Immunity”, Journal of Immunotherapy and Cancer, 2020, 8(Suppl 3):A153. [cited by applicant]
White et al., “Antibody-Targeted Immunotherapy for Treatment of Malignancy”, Annual Review of Medicine, 2001, 52:125-145. [cited by applicant]
Xu et al., “Method to convert N-terminal glutamine to pyroglutamate for characterization of recombinant monoclonal antibodies”, Analytical Biochemistry, 2013, 436(1):10-12. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/US2018/030453, completed on Jul. 31, 2019, 14 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/US2020/048700, mailed on Mar. 10, 2022, 13 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/US2022/072099, mailed on Nov. 16, 2023, 15 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/US2022/072110, mailed on Nov. 16, 2023, 8 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/US2022/072110, mailed on Sep. 12, 2022, 12 pages. [cited by applicant]
Haidar et al., “A universal combinatorial design of antibody framework to graft distinct CDR sequences: A bioinformatics approach”, Proteins: Structure, function, and bioinformatics, 2012, 80(3): 896-912. [cited by applicant]
Mittal et al., “CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function”, Cancer Immunology Research, 2019, 7(4): 559-571. [cited by applicant]